Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06393452 |
Recruitment Status :
Not yet recruiting
First Posted : May 1, 2024
Last Update Posted : May 20, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Androgenetic Alopecia | Drug: PP405 0.05% Topical Gel Drug: PP405 Topical Vehicle Gel | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Efficacy of PP405 in Adults With Androgenetic Alopecia |
Estimated Study Start Date : | June 2024 |
Estimated Primary Completion Date : | December 2024 |
Estimated Study Completion Date : | February 2025 |
Arm | Intervention/treatment |
---|---|
Active Comparator: PP405 0.05% Topical Gel
0.05% Topical Gel applied once daily
|
Drug: PP405 0.05% Topical Gel
PP405 is an inhibitor of mitochondrial pyruvate carrier (MPC) |
Placebo Comparator: PP405 Topical Vehicle Gel
Placebo Topical Gel applied once daily
|
Drug: PP405 Topical Vehicle Gel
PP405 Vehicle = placebo |
- Percentage of subjects with treatment-related adverse events [ Time Frame: Baseline to Day 28 ]Collection of adverse events, treatment emergent adverse events and serious adverse events.
- Change in local dermal tolerability as assessed by subject and investigator [ Time Frame: Baseline to Day 28 ]Collection of local skin reactions using a 4 point scale (0-none, 1-mild, 2-moderate, 3-severe)
- Pharmacokinetics of PP405 [ Time Frame: Baseline to Day 28 ]To assess the concentration of PP405 in plasma
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male or female subjects aged 18 to 55 years.
- Able and willing to provide written informed consent.
- Males must have an AGA modified Norwood-Hamilton Classification score of Type III vertex, Type IV or Type V. Females must have a Savin classification score of I-2, I-3 or I-4.
- Agree to comply with protocol procedures
Exclusion Criteria:
- Concomitant diagnosis of non-AGA forms of alopecia.
- Use of other hair loss treatments within periods specified in protocol.
- Use of excluded medications as specified in protocol.
- Diagnosis of other medical conditions as specified in protocol.
- Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06393452
Contact: Lisa Sherman | 213-218-3830 | clinicaltrials@pelagepharma.com |
Study Chair: | Christina Weng | Pelage Pharmaceuticals |
Responsible Party: | Pelage Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT06393452 |
Other Study ID Numbers: |
PP405-2001 |
First Posted: | May 1, 2024 Key Record Dates |
Last Update Posted: | May 20, 2024 |
Last Verified: | May 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Alopecia Alopecia Areata Hypotrichosis |
Hair Diseases Skin Diseases Pathological Conditions, Anatomical |